CCC Diagnostics Inc Announces Expanded Insurance Coverage for the DirectHit Panel for Breast Cancer
CCC Diagnostics has obtained expanded health care coverage for the DirectHit Panel for Breast Cancer. DirectHit™ provides information about the tumor that may be used its to prescribe the most effective anticancer drug treatment.
Online, January 21, 2011 (Newswire.com) - CCC Diagnostics, Inc (CCCD), announced today that the Centers for Medicare & Medicaid will provide coverage for their Drug Response Indicator Test (DRIT), trademarked as the Breast Cancer DirectHitTM Test Panel. In addition to Medicare, several other major health insurance companies have provided coverage for the test.
The DirectHit Panel™ analyzes an individual patient's tumor in order to indicate the response to commonly prescribed anti-breast cancer chemotherapy drugs. DirectHit™ provides information about the tumor that may be used in addition to the usual tests to prescribe the most effective anticancer drug treatment.
John Hughes, CEO of CCC Diagnostics, commented " We are very pleased with the expanded coverage afforded DirectHit by the major health insurance providers. This expanded coverage will allow more patients to have access to DirectHit testing. Which is a significant step forward for physicians and their patients because the treatment will now have a higher probability of affecting the tumor."
"No longer must one breast cancer treatment fit all," says Mr. Hughes, which should be welcome news for
physicians and their patients."